Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322263 | 0.86 | MAOB (0.53) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25947185 | 0.83 | MAOB (0.57) | MAOBAPPIDO1NPC1HTT | |
| SCHEMBL4323959 | 0.83 | MAOB (0.54) | MAOBAPPMAOAIDO1 | |
| SCHEMBL1578651 | 0.83 | MAOB (0.59) | MAOBAPPMAOACA12CA1 | |
| SCHEMBL8901906 | 0.82 | MAOB (0.56) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1578198 | 0.81 | MAOB (0.43) | MAOBMAOA | |
| Hydrochloric Acid SCHEMBL29763734 | 0.81 | MAOB (0.55) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28293182 | 0.81 | MAOB (0.55) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6054786 | 0.80 | MAOB (0.55) | MAOBAPPMAOAARCA12 | |
| SCHEMBL4322451 | 0.79 | MAOB (0.62) | MAOBMAOAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492588-B2 | Benzyloxy anilide derivatives useful as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120329869-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL | 2012-12-27 | — | — | US | disclosed |
| US-8188314-B2 | Benzyloxy anilide derivatives useful as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329869-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCND2, KCNB2, KCNAB1 | MAOB 549/4885APP 909/4885MAOA 756/4885 |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCND2, KCNB2, KCNAB1 | MAOB 549/4885APP 909/4885MAOA 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.